
In July, a phase III trial study conducted by Swiss biotech firm Roche suggested that the drug “did not demonstrate a benefit for patients in either clinical status or mortality”.
In July, a phase III trial study conducted by Swiss biotech firm Roche suggested that the drug “did not demonstrate a benefit for patients in either clinical status or mortality”.